Tagged with S

USA Industry veteran Peter Anastasiou, executive VP and head of North America for Danish CNS specialist Lundbeck, outlines the performance of Lundbeck’s specialty portfolio in the US market, the challenges of working in the CNS space, and how the company is adapting to the problems posed by the COVID-19 pandemic.  …

Belgium Kevin Houdenaert, general manager for Benelux and the Nordics at Italian rare disease, specialty and primary care specialist Recordati, gives an overview of the market access specificities of the markets he manages, the autonomy that Recordati country managers enjoy, and his main priorities for 2020.   I see a lot…

Japan Ryu Ogawa and Satoshi Tamaki of Japanese AI-powered drug discovery firm Molcure outline how their technology can supercharge the speed and efficiency of the drug discovery process as well as the wider implications for greater use of artificial intelligence in the biotechnology field.   The greatest strength of Molcure’s system…

China Probably one of the most recognisable Chinese biotechs globally, Zai Lab may only be seven years old but the company has progressed rapidly in becoming a NASDAQ-listed company with not just one but two commercial assets through a stunningly effective strategy of forming productive collaborations with the most innovative biopharma…

Merck PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to unpack her important role within the global group and how Merck has pivoted to rise to the supply chain challenges posed by the COVID-19 crisis.   Although many companies now claim to have this…

Opinion As COVID-19 threatens to derail more than a decade’s worth of hard-won gains in the fight against malaria, Dr Benjamin Pretorius, managing director at ERADA Technology Alliance, warns that diversions of malaria resources and interruptions to prevention programmes may cost thousands of lives.   Malaria still takes the lives of…

Russia Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet been completed, critics both from within Russia and internationally have raised concerns as to the vaccine’s safety and efficacy.  …

Long Read Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s zesty life science ecosystem. At first glance, the numbers certainly appear more steady than thrilling: a EUR 5.4 billion domestic…

Opinion In his latest piece, Brendan Shaw casts his eye over why those drawing up health policies need to start incorporating issues of industrial policy into their long-term planning in order to secure investments into the right kinds of R&D and to help build a more open and collaborative innovation ecosystem.…

Pharma Faces Belgium is a vitally important country for Johnson & Johnson’s pharmaceutical arm, Janssen, globally. In addition to their R&D centre and a pharma production plant in Beerse, Janssen also has a chemical production plant in Geel, a Clinical Pharmacology Unit in Merksem, and a Phase I research institute in Antwerp…

Belgium Belgian doctor, researcher and professor, Stéphane De Wit has been with the St Pierre University Hospital in Brussels since 1983. Initially planning to specialize in intensive care, his first internship took him by chance to the infectious diseases department where he encountered his first patients with AIDS, met his mentor,…

Belgium Belgium’s healthcare system was ranked fourth in Europe in 2019, outperforming its peers across a number of metrics including a relatively high number of hospital beds per capita (six per thousand citizens, compared to the EU average of five per thousand citizens) and the second-highest number of doctor consultations per…